Irene Blair was expected to have another six to eight months to live in June, after her pancreatic cancer rapidly advanced to ...

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

Jazz’s Ziihera and BeOne’s Tevimbra plus chemotherapy led to what Truist Securities dubbed one of the strongest overall ...

The decision to end the programme comes 18 months after Genmab's former partner for the acasunlimab, BioNTech, pulled out of ...

Explore how Insilico collaborates with Servier to advance AI-driven drug discovery in oncology for unmet medical needs.

Multi-year partnership with France's Servier will use Insilico's AI platform to explore novel cancer drugs Newly Hong ...

Insilico Medicine (“Insilico”), a world-leading artificial intelligence (AI)-driven drug discovery company, today announced a ...

A redesigned immune-activating cancer drug has produced striking early results in a small clinical trial, shrinking tumors ...

AbbVie and Gilead Sciences each used the holiday season to reward their pipelines with a new clinical-stage cancer drug. | ...

The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial ...

Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...

The discovery could pave the way for new treatments, improved risk prediction, and earlier intervention for brain metastases.